MwanzoALTME • EPA
add
TME Pharma NV
Bei iliyotangulia
€ 0.074
Bei za siku
€ 0.072 - € 0.074
Bei za mwaka
€ 0.061 - € 0.44
Thamani ya kampuni katika soko
6.53M EUR
Wastani wa hisa zilizouzwa
elfu 689.11
Uwiano wa bei na mapato
-
Mgao wa faida
-
Ubadilishanaji wa msingi
EPA
Habari za soko
The Straits Times
siku 1 iliyopita
Nasdaq closes lower, S&P 500 up slightly as US yields stay elevated
1.72%
1.38%
Fedha
Taarifa ya Mapato
Mapato
Mapato halisi
| (EUR) | Jun 2024info | Mabadiliko Tangu Mwaka Uliopita |
|---|---|---|
Mapato | — | — |
Matumizi ya uendeshaji wa biashara | 1.37M | -0.51% |
Mapato halisi | -1.62M | 11.23% |
Kiwango cha faida halisi | — | — |
Mapato kwa kila hisa | — | — |
EBITDA | -1.34M | 0.07% |
Asilimia ya kodi ya mapato | — | — |
Taarifa ya Hali ya Kifedha
Jumla ya mali
Jumla ya dhima
| (EUR) | Jun 2024info | Mabadiliko Tangu Mwaka Uliopita |
|---|---|---|
Uwekezaji wa pesa taslimu na vipindi vifupi | 2.70M | -10.14% |
Jumla ya mali | 2.94M | -15.02% |
Jumla ya dhima | 1.38M | -62.07% |
Jumla ya hisa | 1.57M | — |
hisa zilizosalia | 42.12M | — |
Uwiano wa bei na thamani | 1.85 | — |
Faida inayotokana na mali | -116.29% | — |
Faida inayotokana mtaji | -217.64% | — |
Mtiririko wa pesa
Mabadiliko halisi ya pesa taslimu
| (EUR) | Jun 2024info | Mabadiliko Tangu Mwaka Uliopita |
|---|---|---|
Mapato halisi | -1.62M | 11.23% |
Pesa kutokana na shughuli | -1.37M | 19.42% |
Pesa kutokana na uwekezaji | elfu -4.00 | 57.89% |
Pesa kutokana na ufadhili | 1.60M | 78.88% |
Mabadiliko halisi ya pesa taslimu | elfu 229.00 | 128.17% |
Mtiririko huru wa pesa | elfu -723.12 | 3.18% |
Kuhusu
TME Pharma, formerly NOXXON Pharma, is a biotechnology company founded in 1997 in Berlin, Germany which specialises on cancer treatment by targeting the tumor microenvironment. TME Pharma N.V. is listed on Euronext Growth, Paris and is a member of the German Association of Research-Based Pharmaceutical Companies, Verband forschender Arzneimittelhersteller.
TME Pharma develops drugs using technology yielding L-RNA molecules, which are of mirror-image configuration compared to naturally occurring D-RNA molecules. The company calls these agents Spiegelmers, from Spiegel, the German word for "mirror."
The L-RNA are resistant to the natural RNA nuclease enzymes. Wikipedia
Afisa Mkuu Mtendaji (CEO)
Ilianzishwa
1997
Tovuti
Wafanyakazi
13
